Major Drugs - Melbourne, VIC, AU
Paradigm's (ASX: PAR) immediate commercial focus is the repurposing of Pentosan Polysulfate Sodium (PPS) for the treatment of Osteoarthritis (OA). This is a global unmet need and we have advanced to phase 3 trials in the space. Addressing all aspects of the disease: inflammation, pain, and regeneration, PPS has genuine disease-modifying potential.
Outlook
MailChimp
Mobile Friendly
YouTube